ArticleMolecular biology reports2026
eIF6 affects the occurrence and development of esophageal cancer.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectiveEsophageal cancer (EC) ranks 11th in incidence and 7th in mortality among malignancies globally. The role of eukaryotic translation initiation factor 6 (eIF6) in esophageal squamous cell carcinoma (ESCA) progression, including its involvement in tumor development, invasion, and epithelial-mesenchymal transition (EMT), remains to be fully characterized.
methodsBioinformatic and immunohistochemistry (IHC) analyses of 114 ESCA cases demonstrated eIF6 upregulation, which was associated with lower tumor differentiation. Elevated eIF6 expression in ESCA cell lines (KYSE150, TE-1) relative to normal esophageal epithelial cells (HEEC) was verified by reverse transcription-quantitative PCR and western blotting. eIF6 silencing via short hairpin RNA (shRNA) attenuated ESCA cell proliferation, migration, and colony formation in vitro, as assessed by Cell Counting Kit-8, wound healing, and Transwell assays.
resultsBioinformatic analysis and IHC results showed that eIF6 protein was up-regulated in ESCC, and its expression level was inversely correlated with tumor differentiation degree. eIF6 knockdown was associated with reduced proliferation, migration, and colony formation of ESCC cells, accompanied by shifts in EMT markers, including increased E-cadherin and decreased N-cadherin and Vimentin levels. In addition, eIF6 depletion was accompanied by decreased phosphorylation of AKT (p-AKT
conclusionThese findings indicate an association between eIF6 upregulation and ESCA aggressiveness, along with concomitant changes in the PI3K/AKT/mTOR signaling pathway.
Indexed as
Identifiers
42560586What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.